Evidence map›Paper›PMID 33260907›Full record

ArticleMaterials (Basel, Switzerland)2020

Salecan-Clay Based Polymer Nanocomposites for Chemotherapeutic Drug Delivery Systems; Characterization and In Vitro Biocompatibility Studies.

Paula Ecaterina Florian, Madalina Icriverzi, Claudia Mihaela Ninciuleanu, Elvira Alexandrescu, Bogdan Trica, Silviu Preda, Raluca Ianchis, Anca Roseanu

Open access · goldAbstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Paula Ecaterina FlorianDepartment of Ligand-Receptor Interaction, Institute of Biochemistry of the Romanian Academy, Splaiul Independentei 296, 060031 Bucharest, Romania.ORCID 0000-0002-3322-5682
Madalina IcriverziDepartment of Ligand-Receptor Interaction, Institute of Biochemistry of the Romanian Academy, Splaiul Independentei 296, 060031 Bucharest, Romania.ORCID 0000-0003-0282-1825
Claudia Mihaela NinciuleanuNational R&D Institute for Chemistry and Petrochemistry ICECHIM-Bucharest, Splaiul Independentei 202, 6th District, P.O. Box 35/174, 0600021 Bucharest, Romania.
Elvira AlexandrescuNational R&D Institute for Chemistry and Petrochemistry ICECHIM-Bucharest, Splaiul Independentei 202, 6th District, P.O. Box 35/174, 0600021 Bucharest, Romania.ORCID 0000-0002-5378-692X
Bogdan TricaNational R&D Institute for Chemistry and Petrochemistry ICECHIM-Bucharest, Splaiul Independentei 202, 6th District, P.O. Box 35/174, 0600021 Bucharest, Romania.ORCID 0000-0002-9948-6914
Silviu PredaInstitute of Physical Chemistry "Ilie Murgulescu", Romanian Academy, Spl. Independentei 202, 6th District, P.O. Box 194, 060021 Bucharest, Romania.ORCID 0000-0003-3956-3313
Raluca IanchisNational R&D Institute for Chemistry and Petrochemistry ICECHIM-Bucharest, Splaiul Independentei 202, 6th District, P.O. Box 35/174, 0600021 Bucharest, Romania.ORCID 0000-0002-5540-2774
Anca RoseanuDepartment of Ligand-Receptor Interaction, Institute of Biochemistry of the Romanian Academy, Splaiul Independentei 296, 060031 Bucharest, Romania.
Institutul Naţional de Cercetare Dezvoltare pentru Chimie si Petrochimie · ROInstitute of Biochemistry · RORomanian Academy · RO

Funding

Institute of Biochemistry of the Romanian Academy project number 4/2020Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii PN-III-P2.1-PED-2016-1896Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii PN-III-P2-2.1-PED-2019-4216
6 · The paper itself

Abstract

Salecan is a microbial polysaccharide suitable to obtain hydrogel for biomedical applications due to the excellent hydrophilicity and biocompatibility properties. In this work, Salecan of different concentrations was introduced into polymethacrylic acid (PMAA) in the presence of clay to form novel semi synthetic hydrogel nanocomposites systems and loaded afterwards with doxorubicin (DOX). The physical-chemical characteristics of the nanocomposites systems and their effect on the viability, and morphology of MDBK (Madin-Darby bovine kidney), HT-29 human colorectal adenocarcinoma and Colo 205 human colon adenocarcinoma cell lines were investigated. DOX release from the nanocomposite systems, cell up-take and subsequent effect on cell proliferation was also analyzed. It was found that Salecan concentration determined the swelling behavior, structural parameters and morphological features of the nanocomposite systems. The hydrogen bonds strongly influenced the formation of PMAA-Salecan-clay systems, each component bringing its own contribution, thus demonstrating the achievement of an advanced crosslinked network and a more compacted hydrogel nanocomposite morphology. All the synthesized nanocomposites had negligible toxicity to normal MDBK cells and chemoresistent HT-29 cell line, whereas in the case of Colo 205 cells a decrease by 40% of the cell viability was obtained for the sample containing the highest amount of Salecan. This effect was correlated with the lowest pore size distribution leading to highest available specific surface area and entrapped amount of DOX which was further released from the nanocomposite sample. Corroborating all the data it can be suggested that the synthesized nanocomposites with Salecan and clay could be good candidates as vehicles for chemotherapeutic agents.

Indexed as

claydoxorubicinnanocompositesSalecan

Identifiers

PMID33260907
PMCPMC7730270
OpenAlexW3107244831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.